The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.It should be noted that the reported patient effects of ischemia and dyspnea are listed in the xience sierra, everolimus eluting coronary stent system instructions for use as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effect(s), and the relationship to the product, if any, cannot be determined; however, the reported treatments appear to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling of the device.
|
Patient id: (b)(6).It was reported that on (b)(6) 2020, the patient presented with angina, severe calcification within the left anterior descending (lad) coronary artery, and a mid-lad, 80% stenosed lesion.Pre-dilatation was performed and a 3.0x18mm xience sierra stent was implanted with acceptable results and no complications.Timi flow iii with 0% residual stenosis was observed.On (b)(6) 2020, the patient expressed experiencing fatigue and dyspnea during a follow-up visit.A stress test was performed and a large area of perfusion defect was observed in the lad area.Regarding the xience sierra stent, there was no restenosis and no device malfunction.As treatment, a new stent was placed within the proximal lad and medications were provided.The event did not require hospitalization.There was no device malfunction.No additional information was provided regarding this issue.
|